Stockpolly
Search
ACTU · NASDAQ · Biotechnology

Actuate Therapeutics (ACTU)

Develops elraglusib, a GSK-3β inhibitor, for metastatic pancreatic cancer.

$1.37
Pre-market+0.07 (+4.98%)
At close$1.31(−15.26%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
688557665565
Research & development677444332232
111123333333
General & administrative111123333033
Operating income−6−8−8−5−5−7−6−6−5−5−6−5
00−1−1−10000000
Interest income000000000000
Interest expense000000000000
Other non-operating income001110000000
Income before tax−6−8−8−7−6−6−6−6−5−5−6−5
Income tax expense000000000000
Net income from continuing operations−6−8−8−7−6−6−6−6−5−5−6−5
Net income−6−8−8−7−6−6−6−6−5−5−6−5
EPS, basic−$0.41−$0.50−$0.54−$0.34−$0.55−$0.60−$0.32−$0.30−$0.25−$0.20−$0.24−$0.20
EPS, diluted−$0.41−$0.50−$0.54−$0.34−$0.55−$0.60−$0.32−$0.30−$0.25−$0.20−$0.24−$0.20
Weighted average shares, basic151515202020192021232424
Weighted average shares, diluted151515202020192021232424
EBITDA−6−8−8−7−6−6−6−6−5−5−6−5
Depreciation & amortization000000000000
EBIT−6−8−8−7−6−6−6−6−5−5−6−5